30 Mar 2011
US-based Merck and France based sanofi-aventis have terminated their agreement to form a new animal health joint venture by combining sanofi-aventis’ animal health business Merial with Intervet/Schering-Plough, Merck's animal health unit.
Related
LinkAsia Partners appoints Thai distributor
Provimi sells pet food activities to Advent...
Pfizer Animal Health begins integration with...
As a result, each party will keep its current, separate animal health assets and businesses.
Since the initial announcement about the intended combination on March 9, 2010, both companies have worked diligently to create the proposed animal health joint venture, including submitting requests for the required antitrust reviews.
Antitrust obstacles
The merger was aborted because antitrust authorities insisted that both parties should divest some divisions.
Due to the animal health merger the companies were obliged to divest activities with a value of $500 million. Particularly in the field of poultry health the new entity would become too dominant.
As a result of termination, both Merial and Intervet/Schering-Plough will continue to operate independently. The termination of the agreement is without penalty to either party and each party is responsible for its own expenses
30 March 2011
29 March 2011
JSR breeding pigs make it to China
//29 Mar 2011
Over eight-hundred high health, genetically advanced breeding pigs have successfully touched down in China this week. The animals were transported from the UK onboard a specially chartered 747 aircraft on behalf of JSR Genetics.
The pigs are the first shipment to Guangzhou Animal Husbandry Company (GZAH), based in Guangzhou province, which will stock a new breeding Nucleus farm. The pigs were JSR Genepacker GGP Gilts and JSR Geneconverter GGP Boars, and all arrived safely into their Chinese isolation.
“This is a great success for JSR and the start of a long business relationship with GZAH” comments Paul Anderson, International Sales Director, JSR. “Following the signing of the contract in Beijing in November 2010, attended by Vince Cable, UK Business Secretary, a lot of work has been put in to ensure we delivered successfully on the contract.”
The pigs were accompanied by Darren Farnsworth, JSR’s Export Coordinator. “The flight went very much to plan; the pigs were delivered on time, safely and in good health. We are especially thankful to DEFRA for helping to negotiate some last minute issues with the Chinese authorities.” This was the first shipment of British pigs delivered under the new, more demanding Chinese health certificate.
China is home to half the world’s pigs and pork consumption is growing as the Chinese choose to eat more meat. This is therefore the most important world market for JSR and will be the major source of growth for the Company over the next 10 years.
Mr Wen Wei Long of the Guangzhou Animal Husbandry Company comments, “We are satisfied that JSR not only provide world class genetics but also the on-going technological support we need to fully realise the potential of our investment here in Guangzhou.”
For more information www.jsr.co.uk
Over eight-hundred high health, genetically advanced breeding pigs have successfully touched down in China this week. The animals were transported from the UK onboard a specially chartered 747 aircraft on behalf of JSR Genetics.
The pigs are the first shipment to Guangzhou Animal Husbandry Company (GZAH), based in Guangzhou province, which will stock a new breeding Nucleus farm. The pigs were JSR Genepacker GGP Gilts and JSR Geneconverter GGP Boars, and all arrived safely into their Chinese isolation.
“This is a great success for JSR and the start of a long business relationship with GZAH” comments Paul Anderson, International Sales Director, JSR. “Following the signing of the contract in Beijing in November 2010, attended by Vince Cable, UK Business Secretary, a lot of work has been put in to ensure we delivered successfully on the contract.”
The pigs were accompanied by Darren Farnsworth, JSR’s Export Coordinator. “The flight went very much to plan; the pigs were delivered on time, safely and in good health. We are especially thankful to DEFRA for helping to negotiate some last minute issues with the Chinese authorities.” This was the first shipment of British pigs delivered under the new, more demanding Chinese health certificate.
China is home to half the world’s pigs and pork consumption is growing as the Chinese choose to eat more meat. This is therefore the most important world market for JSR and will be the major source of growth for the Company over the next 10 years.
Mr Wen Wei Long of the Guangzhou Animal Husbandry Company comments, “We are satisfied that JSR not only provide world class genetics but also the on-going technological support we need to fully realise the potential of our investment here in Guangzhou.”
For more information www.jsr.co.uk
28 March 2011
Ceva finishes first decade of success with strong growth
//25 Mar 2011
Ceva Santé Animale (Ceva) recorded strong growth for the tenth consecutive year with sales of € 468m (+18.5%), including partial sales from the latest acquisitions.
On a proforma basis, sales passed the 500 million euro barrier for the first time (€ 503m). The result was favorably impacted by foreign exchange gains, with overall sales growth of 9.3% after adjustment.
Record levels of R&D and industrial investments were made to support the group’s innovation strategy, with R&D investments reaching € 42m (9% of sales).Market conditions were particularly favorable, especially in fast-emerging economies such as Brazil, South Africa and Turkey where Ceva has a strong presence.
Two acquisitions, Summit VetPharm (SVP) in the United States and Nature Vet in Australia, significantly increased Ceva’s position in key segments of the companion animal market. Due to sales seasonality, the late-August acquisition of SVP had marginal impact on 2010 results. Strategically, the move allows Ceva to enter the single largest market sector of the global animal health market: companion animal parasiticides.
Nature Vet, a specialist equine and companion animal business, performed particularly well with strong sales and earnings growth both in Australia and export markets.
At the infrastructural level, the group continued to make large investments in its manufacturing and
distribution capacity to support existing and anticipated growth. The company completed construction of a new facility at its biotechnology campus in Lenexa, Kansas (US) to produce vector vaccines. A new distribution center and administrative building was added to the headquarters in Libourne, France.
Commenting on the 2010 results, Chairman and CEO Dr. Marc Prikazsky said, “2010 was an impressive year for Ceva as we completed our first 10-year plan ahead of our objectives. We achieved solid growth yet again, aided in part by favorable market conditions. I was particularly pleased to see the strong contribution from our subsidiaries in Brazil, South Africa and Turkey, which illustrates the importance of our investments in rapidly-emerging economies. The successful roll-out of our innovative vector vaccines and new products for companion animals illustrates our value in bringing new technologies to new markets.”
Source: Ceva
Ceva Santé Animale (Ceva) recorded strong growth for the tenth consecutive year with sales of € 468m (+18.5%), including partial sales from the latest acquisitions.
On a proforma basis, sales passed the 500 million euro barrier for the first time (€ 503m). The result was favorably impacted by foreign exchange gains, with overall sales growth of 9.3% after adjustment.
Record levels of R&D and industrial investments were made to support the group’s innovation strategy, with R&D investments reaching € 42m (9% of sales).Market conditions were particularly favorable, especially in fast-emerging economies such as Brazil, South Africa and Turkey where Ceva has a strong presence.
Two acquisitions, Summit VetPharm (SVP) in the United States and Nature Vet in Australia, significantly increased Ceva’s position in key segments of the companion animal market. Due to sales seasonality, the late-August acquisition of SVP had marginal impact on 2010 results. Strategically, the move allows Ceva to enter the single largest market sector of the global animal health market: companion animal parasiticides.
Nature Vet, a specialist equine and companion animal business, performed particularly well with strong sales and earnings growth both in Australia and export markets.
At the infrastructural level, the group continued to make large investments in its manufacturing and
distribution capacity to support existing and anticipated growth. The company completed construction of a new facility at its biotechnology campus in Lenexa, Kansas (US) to produce vector vaccines. A new distribution center and administrative building was added to the headquarters in Libourne, France.
Commenting on the 2010 results, Chairman and CEO Dr. Marc Prikazsky said, “2010 was an impressive year for Ceva as we completed our first 10-year plan ahead of our objectives. We achieved solid growth yet again, aided in part by favorable market conditions. I was particularly pleased to see the strong contribution from our subsidiaries in Brazil, South Africa and Turkey, which illustrates the importance of our investments in rapidly-emerging economies. The successful roll-out of our innovative vector vaccines and new products for companion animals illustrates our value in bringing new technologies to new markets.”
Source: Ceva
Merck and sanofi-aventis terminate animal health agreement
//23 Mar 2011
Merck and sanofi-aventis have announced the mutual termination of their agreement to form a new animal health joint venture by combining Merial, the animal health business of sanofi-aventis, with Intervet/Schering-Plough, Merck's animal health unit. As a result, each party will keep its current, separate animal health assets and businesses.
Since the initial announcement about the intended combination on March 9, 2010, both companies have worked diligently to create the proposed animal health joint venture, including submitting requests for the required antitrust reviews. The companies are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process. Merck and sanofi-aventis mutually determined that ending their plan is in the best interests of both companies and their respective shareholders, as well as the employees of Merial and Intervet/Schering Plough.
Sanofi-aventis remains strongly committed to its animal health activities, which it will continue to develop under the Merial brand as a growth platform of its diversified health business. Merial is one of the world's leading innovation-driven animal healthcare companies dedicated to research, development, manufacturing and commercialization of veterinary pharmaceuticals and vaccines, that generated annual sales of US $ 2.6 billion in 2010.
As a result of termination, both Merial and Intervet/Schering-Plough will continue to operate independently. The termination of the agreement is without penalty to either party and each party is responsible for its own expenses
Merck and sanofi-aventis have announced the mutual termination of their agreement to form a new animal health joint venture by combining Merial, the animal health business of sanofi-aventis, with Intervet/Schering-Plough, Merck's animal health unit. As a result, each party will keep its current, separate animal health assets and businesses.
Since the initial announcement about the intended combination on March 9, 2010, both companies have worked diligently to create the proposed animal health joint venture, including submitting requests for the required antitrust reviews. The companies are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process. Merck and sanofi-aventis mutually determined that ending their plan is in the best interests of both companies and their respective shareholders, as well as the employees of Merial and Intervet/Schering Plough.
Sanofi-aventis remains strongly committed to its animal health activities, which it will continue to develop under the Merial brand as a growth platform of its diversified health business. Merial is one of the world's leading innovation-driven animal healthcare companies dedicated to research, development, manufacturing and commercialization of veterinary pharmaceuticals and vaccines, that generated annual sales of US $ 2.6 billion in 2010.
As a result of termination, both Merial and Intervet/Schering-Plough will continue to operate independently. The termination of the agreement is without penalty to either party and each party is responsible for its own expenses
Bird flu strain discovered in the Netherlands
//25 Mar 2011
A H7 strain of bird flu has been discovered on a poultry farm in the Netherlands, the Dutch government has confirmed.
The bird flu strain was detected at a poultry farm in the municipality of Kapelle, located in the province of Zeeland, the Dutch Ministry of Economic Affairs, Agriculture and Innovation acknowledged in a statement.
The Ministry stated that the outbreak involved the H7 variant but that the exact subtype of the bird flu virus was not yet known, noting that the low pathogenic variant is able to mutate into a highly pathogenic variant.
In compliance with European rules, all 127,500 chickens at the poultry farm will be culled immediately and a movement ban applying to poultry, eggs, poultry manure, poultry litter and poultry food for a radius of 1 kilometer has been announced.
Wild birds are the likely source of infection according to the Ministry. In 2003, the Netherlands was hit by an epidemic of the H7N7 bird flu strain, resulting in the cull of more than 25 million birds.
A H7 strain of bird flu has been discovered on a poultry farm in the Netherlands, the Dutch government has confirmed.
The bird flu strain was detected at a poultry farm in the municipality of Kapelle, located in the province of Zeeland, the Dutch Ministry of Economic Affairs, Agriculture and Innovation acknowledged in a statement.
The Ministry stated that the outbreak involved the H7 variant but that the exact subtype of the bird flu virus was not yet known, noting that the low pathogenic variant is able to mutate into a highly pathogenic variant.
In compliance with European rules, all 127,500 chickens at the poultry farm will be culled immediately and a movement ban applying to poultry, eggs, poultry manure, poultry litter and poultry food for a radius of 1 kilometer has been announced.
Wild birds are the likely source of infection according to the Ministry. In 2003, the Netherlands was hit by an epidemic of the H7N7 bird flu strain, resulting in the cull of more than 25 million birds.
Thailand: Betagro Group in provincial drive
//28 Mar 2011
Betagro Group will invest Baht 1 billion in six upcountry sites, mainly in the south, focused on business expansion, extending the number of slaughterhouses, processing plants, feed mills, distribution centres and shops.
The expansions, to be carried out from 2010 to 2012, will help drive sales of the regional business to 38 billion baht by the end of 2012, up from an estimated 29.3 billion baht this year, says Vasit Taepaisitphongse, Betagro chief operating officer.
Vasit added that it is also expanding its business into neighbouring countries, including Laos and Cambodia, for livestock and feed mills, with construction of a pig farm in Cambodia "40% complete" and a feed mill in Laos with a monthly capacity of 6,000 tonnes.
(By Joyce Rainat)
Betagro Group will invest Baht 1 billion in six upcountry sites, mainly in the south, focused on business expansion, extending the number of slaughterhouses, processing plants, feed mills, distribution centres and shops.
The expansions, to be carried out from 2010 to 2012, will help drive sales of the regional business to 38 billion baht by the end of 2012, up from an estimated 29.3 billion baht this year, says Vasit Taepaisitphongse, Betagro chief operating officer.
Vasit added that it is also expanding its business into neighbouring countries, including Laos and Cambodia, for livestock and feed mills, with construction of a pig farm in Cambodia "40% complete" and a feed mill in Laos with a monthly capacity of 6,000 tonnes.
(By Joyce Rainat)
25 March 2011
Massive culling of pigs takes place in Taiwan
//24 Mar 2011
Pigs that were affected by Foot-and-Mouth disease in Taiwan have been culled. It has been stated that 999 pigs have been culled thus far on Penghu Island due to the disease.
Taiwan's epidemic prevention authorities confirmed the culling. Currently, 3000 pigs are quarantined.
Most serious FMD outbreak
According to a report, this current outbreak is the worst seen in the past three years on the island.
It is not permitted at this moment for pork or live pigs to be transporteed in or out of Penghu, as there is fear of the disease spreading.
Taiwan' s cloven hooves production has been restricted for export since 1997- when Foot-and-Mouth epidemic was rife in the region. Other animals are under close monitoring by epidemic prevention officers in Penghu as well as on mainland Taiwan.
Source: China.org.cn
Pigs that were affected by Foot-and-Mouth disease in Taiwan have been culled. It has been stated that 999 pigs have been culled thus far on Penghu Island due to the disease.
Taiwan's epidemic prevention authorities confirmed the culling. Currently, 3000 pigs are quarantined.
Most serious FMD outbreak
According to a report, this current outbreak is the worst seen in the past three years on the island.
It is not permitted at this moment for pork or live pigs to be transporteed in or out of Penghu, as there is fear of the disease spreading.
Taiwan' s cloven hooves production has been restricted for export since 1997- when Foot-and-Mouth epidemic was rife in the region. Other animals are under close monitoring by epidemic prevention officers in Penghu as well as on mainland Taiwan.
Source: China.org.cn
Subscribe to:
Posts (Atom)